Drug intelligence / Profile preview

betamethasone + cyclosporine + methotrexate

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intraarticular

Overview

A combination therapy consisting of methotrexate (a disease-modifying antirheumatic drug), cyclosporine (an immunosuppressant), and intraarticular betamethasone (a corticosteroid). This regimen is used primarily for treating early active rheumatoid arthritis. Clinical studies have shown that this combination provides excellent disease control and can stop the progression of joint erosions in patients with early active RA who have a poor prognosis. The addition of cyclosporine to methotrexate and betamethasone improves certain clinical responses (ACR20 and ACR-N).

Targets

GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)PPIA (Peptidyl-prolyl cis-trans isomerase A)CN (Calcineurin)

Beyond the preview

Go deeper on betamethasone + cyclosporine + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + cyclosporine + methotrexate.

Explore the full profile